Phase 1 N=14 The Safety and Immunogenicity of a Potential HIV Vaccine
HIV Infections
Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=711 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Week 26) — -1.2; -1.1; -0.1; -1.4 Percentage of HbA1c — p=<0.0001
N/A N=9 Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity
Cardiovascular Diseases
Primary: Optical Platelet Aggregometry — -13; -35; 7; -57.5 percentage of maximal aggregation
N/A N=57 Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
N/A N=27 The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
Glaucoma, Open-angle · Hypertension, Ocular
Primary: Change in Intraocular Pressure From Baseline at Visit 3 — 21.1; 18.2; 20.0; 17.1 mmHg
Phase 1 N=16 A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) for Balovaptan — 94.2; 12.9 ng/mL
Phase 3 N=731 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Week 26) — -0.5; -1.0; -1.3; -0.1 Percentage of HbA1c — p=< 0.0001
Phase 3 N=4,125 Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis
Primary: Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death — 2125; 515; 16 Participants
Phase 1 N=28 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
HIV Infections
Primary: Frequency of Grade 2 or Higher Adverse Events (AEs) — 3; 5 Participants — p=0.072
N/A N=12 Colonic Propionate, Appetite, and Weight Loss
Healthy Obesity, Metabolically · Appetite Regulation
Primary: Change in Weight Loss Compared to Baseline — -2.6; -3 kg — p=0.8
N/A N=97 Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Skin Cancer · Actinic Keratoses · Ultraviolet-Induced Change in Normal Skin
Primary: Quantification of Actinic Keratosis Using the UV Sensor vs. Control Group — 4.53; 4.74 lesions — p=0.8
N/A N=60 Effect of Fibre Products on Appetite and Weight
Obesity
Primary: Appetite_Food Intake — 678; 836; 645; 763 kcal — p=0.972
N/A N=156 Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
Barrett Esophagus
Primary: Number of Participants Reporting Each Category of Tolerance Assessed by the Tolerance Survey — 96; 31; 1; 121 number of participants
N/A N=54 Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.
Paroxysmal Atrial Fibrillation
Primary: Number of Subjects Achieved Acute Procedural Success — 52 Participants
N/A N=30 A Comparative, Controlled, Clinical Investigation and Quality Control of a New Hearing Aid
Hearing Loss
Primary: Speech Intelligibility Performance — -1.25; -3.89; -5.22 dB SNR